Boston Scientific Corporation (NYSE:BSX) Holdings Lifted by NS Partners Ltd

NS Partners Ltd boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 1.6% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 368,189 shares of the medical equipment provider’s stock after buying an additional 5,704 shares during the period. Boston Scientific accounts for 1.6% of NS Partners Ltd’s investment portfolio, making the stock its 19th largest position. NS Partners Ltd’s holdings in Boston Scientific were worth $37,143,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also bought and sold shares of the company. Bank Pictet & Cie Europe AG lifted its holdings in shares of Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock valued at $6,529,000 after buying an additional 21,173 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in shares of Boston Scientific by 18.8% during the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider’s stock valued at $3,987,000 after purchasing an additional 6,264 shares during the period. Segall Bryant & Hamill LLC acquired a new stake in Boston Scientific in the 1st quarter valued at $8,234,000. Blue Trust Inc. boosted its stake in Boston Scientific by 13.0% in the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider’s stock valued at $504,000 after buying an additional 575 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S boosted its stake in Boston Scientific by 109.9% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 270,107 shares of the medical equipment provider’s stock worth $24,126,000 after purchasing an additional 141,398 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the subject of a number of recent research reports. Needham & Company LLC restated a “buy” rating and set a $115.00 target price on shares of Boston Scientific in a research report on Wednesday, May 28th. Erste Group Bank upgraded Boston Scientific to a “strong-buy” rating in a report on Thursday, May 8th. Citigroup restated a “buy” rating and issued a $125.00 price target (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, Barclays lifted their price objective on Boston Scientific from $125.00 to $133.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Two equities research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $117.50.

Insider Transactions at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of Boston Scientific stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,347,824.96. The trade was a 24.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 345,029 shares of company stock worth $35,976,603 in the last quarter. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.1%

NYSE BSX opened at $102.89 on Friday. The stock’s 50 day moving average is $103.58 and its 200 day moving average is $102.04. Boston Scientific Corporation has a twelve month low of $74.01 and a twelve month high of $108.94. The firm has a market capitalization of $152.46 billion, a PE ratio of 61.25, a P/E/G ratio of 2.48 and a beta of 0.66. The company has a quick ratio of 0.88, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the business posted $0.62 EPS. Boston Scientific’s revenue was up 22.8% on a year-over-year basis. Research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.